These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 397064)

  • 1. Treatment of gram-negative bacteremia with antiserum to core glycolipid II. A controlled trial of antiserum in patients with bacteremia.
    McCutchan JA; Ziegler EJ; Braude AI
    Eur J Cancer (1965); 1979; 15 Suppl():77-80. PubMed ID: 397064
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of gram-negative bacteremia with antiserum to core glycolipid. I. The experimental basis of immunity to endotoxin.
    Ziegler EJ; McCutchan JA; Braude AI
    Eur J Cancer (1965); 1979; 15 Suppl():71-6. PubMed ID: 397063
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
    Ziegler EJ; McCutchan JA; Fierer J; Glauser MP; Sadoff JC; Douglas H; Braude AI
    N Engl J Med; 1982 Nov; 307(20):1225-30. PubMed ID: 6752708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiserum treatment of gram-negative bacteremia.
    Braude AI; Ziegler EJ; McCutchan JA
    Schweiz Med Wochenschr; 1978 Dec; 108(48):1872-6. PubMed ID: 362528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infections in patients with prolonged neutropenia.
    McCutchan JA; Wolf JL; Ziegler EJ; Braude AI
    Schweiz Med Wochenschr Suppl; 1983; 14():40-5. PubMed ID: 6361990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of human gram-negative bacteremia with antiserum against endotoxin core.
    Ziegler EJ; McCutchan JA; Douglas H; Braude AI
    Trans Assoc Am Physicians; 1981; 94():39-43. PubMed ID: 7046193
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of gram-negative bacteremia with antiserum to mutant E. coli.
    Tierney WM
    N Engl J Med; 1983 Apr; 308(17):1032. PubMed ID: 6339930
    [No Abstract]   [Full Text] [Related]  

  • 10. The treatment of gram-negative bacteremia and shock.
    Wolff SM
    N Engl J Med; 1982 Nov; 307(20):1267-8. PubMed ID: 7133058
    [No Abstract]   [Full Text] [Related]  

  • 11. Functional role of antibody against "core" glycolipid of Enterobacteriaceae.
    Young LS; Stevens P; Ingram J
    J Clin Invest; 1975 Oct; 56(4):850-61. PubMed ID: 1099119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial.
    Calandra T; Glauser MP; Schellekens J; Verhoef J
    J Infect Dis; 1988 Aug; 158(2):312-9. PubMed ID: 3136210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization against nosocomial infection.
    Braude AI; Ziegler EJ; McCutchan JA; Douglas H
    Am J Med; 1981 Feb; 70(2):463-6. PubMed ID: 7008592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprophylaxis of gram-negative infections: background for a prophylactic study of purified anticore-glycolipid immunoglobulins in neutropenic patients.
    Glauser MP
    Schweiz Med Wochenschr Suppl; 1983; 14():35-9. PubMed ID: 6361989
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum.
    Ziegler EJ; McCutchan JA; Douglas H; Braude AI
    Trans Assoc Am Physicians; 1975; 88():101-8. PubMed ID: 772922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effect of Re-LPS antiserum on experimental multiple system organ failure.
    Yao YM; Tian HM; Wang YP; Sheng ZY; Shi ZG; Xu SH
    Chin Med J (Engl); 1992 Oct; 105(10):833-8. PubMed ID: 1291201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-endotoxin core glycolipid antibody: the preparation of immune serum of E. Coli J5].
    Xu XN; Li ZJ; Li YP
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Jun; 16(6):358-60. PubMed ID: 15182450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia.
    Braude AI; Ziegler EJ; Douglas H; McCutchan JA
    J Infect Dis; 1977 Aug; 136 Suppl():S167-73. PubMed ID: 330776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Condie RM; Cerra FB
    Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.